DORADO-AC-EX - A Long-Term Safety Extension Study to the Phase 3 DORADOC-AC Study (Protocol DAR-312) of Darusentan in Resistant Hypertension
Clinical trial NCT00389675 · TERMINATED
Trial details
- NCT number
- NCT00389675
- Sponsor
- Gilead Sciences
- Status
- TERMINATED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2007-05-01
- Primary completion
- 2010-02-01
- Enrollment
- 661
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.